S2332-119

Introduced

To require research with respect to fentanyl and xylazine test strips, to authorize the use of grant funds for such test strips, and for other purposes.

119th Congress Introduced Jul 17, 2025

Summary

What This Bill Does

This bill expands federal programs to help communities fight opioid overdose deaths by making fentanyl and xylazine test strips more accessible. Test strips allow people to check substances for deadly contaminants before use, potentially preventing fatal overdoses.

Who Benefits and How

  • People who use drugs and their families benefit from increased access to test strips that can detect deadly fentanyl contamination, potentially saving lives.
  • First responders (EMTs, firefighters, police) receive training and resources to carry and distribute test strips in their communities.
  • Test strip manufacturers gain clearer regulatory pathways and research frameworks to develop and market improved testing technology.
  • Substance use disorder treatment providers may see increased patient engagement as test strip access is linked to treatment referrals.

Who Bears the Burden and How

  • State and tribal health departments must implement expanded grant programs and coordinate test strip distribution.
  • FDA and HHS must develop new research and marketing frameworks for test strip technology.
  • No significant new costs or restrictions are imposed on private industry or the general public.

Key Provisions

  • Allows existing 21st Century Cures Act grants to fund fentanyl/xylazine test strips (Section 2)
  • Requires first responder training programs to include test strip education (Section 3)
  • Directs HHS to create research and regulatory frameworks for test strip technology (Section 4)
  • Mandates a 2-year study on test strip effectiveness in reducing overdose deaths (Section 5)

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

Expands federal efforts to combat opioid overdose deaths by facilitating access to fentanyl and xylazine test strips through grants, first responder training, and research frameworks.

Key Policy Areas

Public Health, Drug Policy, First Responder Training, Medical Research

Primary Purpose

Expands federal efforts to combat opioid overdose deaths by facilitating access to fentanyl and xylazine test strips through grants, first responder training, and research frameworks.

Policy Domains

Public Health Drug Policy First Responder Training Medical Research

ALERT Communities Act

Identified Gains
  • People who use drugs
  • First responders
  • Test strip manufacturers
  • Substance use disorder treatment providers
  • Public health departments
Model: N/A | Version: bill_summary_v2 | Source: is
People who use drugs:
Test strip manufacturers:
Public health departments:
Substance use disorder treatment providers:
Identified Costs
  • HHS and FDA (administrative burden)
  • State health departments (implementation)
Model: N/A | Version: bill_summary_v2 | Source: is
HHS and FDA (administrative burden): ,
State health departments (implementation):

Legislative Progress

Introduced
Introduced Committee Passed
Jul 17, 2025

Ms. Hassan (for herself and Mr. Cornyn) introduced the following …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Manufacturing
2 mentions across 2 clauses
+2 positive

Test strip manufacturers and distributors, Test strip technology manufacturers

Government
2 mentions across 2 clauses
-2 negative

FDA and HHS regulatory offices, HHS research and policy offices

Research & Science
2 mentions across 2 clauses
+2 positive

Public health researchers and academics, Research institutions studying drug detection technology

State & Local Government
1 mention across 1 clause
+1 positive

State and tribal health departments administering opioid response grants

General Public
1 mention across 1 clause
+1 positive

People who use drugs and their families

Outpatient Care Centers
1 mention across 1 clause
+1 positive

Substance use disorder treatment providers

Medical Laboratories
1 mention across 1 clause
+1 positive

Clinical laboratories and point-of-care testing facilities

3/5
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Public Health Drug Policy
Actor Mappings
"the_secretary"
→ Secretary of Health and Human Services
"the_commissioner"
→ Commissioner of Food and Drugs
"the_director_nih"
→ Director of the National Institutes of Health
"the_administrator"
→ Administrator of the Drug Enforcement Administration
"the_director_ondcp"
→ Director of the Office of National Drug Control Policy

Key Definitions

Terms defined in this bill

1 term
"ALERT Communities Act" §S1

Advancing Lifesaving Efforts with Rapid Test strips for Communities Act

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology